265 related articles for article (PubMed ID: 26219757)
21. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis.
Htike ZZ; Zaccardi F; Papamargaritis D; Webb DR; Khunti K; Davies MJ
Diabetes Obes Metab; 2017 Apr; 19(4):524-536. PubMed ID: 27981757
[TBL] [Abstract][Full Text] [Related]
22. Improved glycaemia correlates with liver fat reduction in obese, type 2 diabetes, patients given glucagon-like peptide-1 (GLP-1) receptor agonists.
Cuthbertson DJ; Irwin A; Gardner CJ; Daousi C; Purewal T; Furlong N; Goenka N; Thomas EL; Adams VL; Pushpakom SP; Pirmohamed M; Kemp GJ
PLoS One; 2012; 7(12):e50117. PubMed ID: 23236362
[TBL] [Abstract][Full Text] [Related]
23. Glucagon-like peptide-1 analogues in monogenic syndromic obesity: Real-world data from a large cohort of Alström syndrome patients.
Ali S; Baig S; Wanninayake S; da Silva Xavier G; Dawson C; Paisey R; Geberhiwot T
Diabetes Obes Metab; 2024 Mar; 26(3):989-996. PubMed ID: 38151964
[TBL] [Abstract][Full Text] [Related]
24. [Twice-daily and weekly exenatide: clinical profile of two pioneer formulations in incretin therapy].
Lecube A; Bueno M; Suárez X
Med Clin (Barc); 2014 Sep; 143 Suppl 2():23-7. PubMed ID: 25437462
[TBL] [Abstract][Full Text] [Related]
25. Effects of exenatide in poorly controlled type 2 diabetes.
Kaimal N; Schofield J; Zaki A; Patel R; Sharma M; McCourt E; Imtiaz KE
QJM; 2012 Apr; 105(4):321-6. PubMed ID: 22056400
[TBL] [Abstract][Full Text] [Related]
26. [New blood glucose-lowering drugs in type 2 diabetes: a review of the literature].
Kleefstra N; van Hateren KJ; Houweling ST; Verhoeven S; Kooy A; Goudswaard AN; Bilo HJ
Ned Tijdschr Geneeskd; 2010; 154():A886. PubMed ID: 20298625
[TBL] [Abstract][Full Text] [Related]
27. Predictive factors associated with primary failure to exenatide and non goal attainment in patients with type 2 diabetes.
Preumont V; Hermans MP; Bergman M; Buysschaert M
Acta Clin Belg; 2012; 67(6):411-5. PubMed ID: 23340146
[TBL] [Abstract][Full Text] [Related]
28. Emerging new therapies for the treatment of type 2 diabetes mellitus: glucagon-like peptide-1 receptor agonists.
Lindamood CA; Taylor JR
Clin Ther; 2015 Mar; 37(3):483-93. PubMed ID: 25659912
[TBL] [Abstract][Full Text] [Related]
29. Psychological and quality of life changes in patients using GLP-1 analogues.
Grant P; Lipscomb D; Quin J
J Diabetes Complications; 2011; 25(4):244-6. PubMed ID: 21601480
[TBL] [Abstract][Full Text] [Related]
30. Correlation between baseline characteristics and clinical outcomes in a large population of diabetes patients treated with liraglutide in a real-world setting in Italy.
Lapolla A; Frison V; Bettio M; Dal Pos M; Rocchini P; Panebianco G; Tadiotto F; Da Tos V; D'Ambrosio M; Marangoni A; Ferrari M; Pianta A; Balzano S; Confortin L; Lamonica M; Marin N; Strazzabosco M; Brun E; Mesturino CA; Simoncini M; Zen F; Bax G; Bonsembiante B; Cardone C; Dal Frà MG; Gallo A; Masin M; Piarulli F; Sartore G; Simioni N
Clin Ther; 2015 Mar; 37(3):574-84. PubMed ID: 25626486
[TBL] [Abstract][Full Text] [Related]
31. Determining predictors of early response to exenatide in patients with type 2 diabetes mellitus.
Khan M; Ouyang J; Perkins K; Nair S; Joseph F
J Diabetes Res; 2015; 2015():162718. PubMed ID: 25688374
[TBL] [Abstract][Full Text] [Related]
32. Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics)--preclinical and clinical results.
Madsbad S
Best Pract Res Clin Endocrinol Metab; 2009 Aug; 23(4):463-77. PubMed ID: 19748064
[TBL] [Abstract][Full Text] [Related]
33. The value of short- and long-acting glucagon-like peptide-1 agonists in the management of type 2 diabetes mellitus: experience with exenatide.
Guo XH
Curr Med Res Opin; 2016; 32(1):61-76. PubMed ID: 26439329
[TBL] [Abstract][Full Text] [Related]
34. An overview of once-weekly glucagon-like peptide-1 receptor agonists--available efficacy and safety data and perspectives for the future.
Madsbad S; Kielgast U; Asmar M; Deacon CF; Torekov SS; Holst JJ
Diabetes Obes Metab; 2011 May; 13(5):394-407. PubMed ID: 21208359
[TBL] [Abstract][Full Text] [Related]
35. Dulaglutide: the newest GLP-1 receptor agonist for the management of type 2 diabetes.
Thompson AM; Trujillo JM
Ann Pharmacother; 2015 Mar; 49(3):351-9. PubMed ID: 25565404
[TBL] [Abstract][Full Text] [Related]
36. Efficacy of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight, eating behavior, and glycemic control, in Japanese obese type 2 diabetes.
Fujishima Y; Maeda N; Inoue K; Kashine S; Nishizawa H; Hirata A; Kozawa J; Yasuda T; Okita K; Imagawa A; Funahashi T; Shimomura I
Cardiovasc Diabetol; 2012 Sep; 11():107. PubMed ID: 22973968
[TBL] [Abstract][Full Text] [Related]
37. Effect of exenatide QW or placebo, both added to titrated insulin glargine, in uncontrolled type 2 diabetes: The DURATION-7 randomized study.
Guja C; Frías JP; Somogyi A; Jabbour S; Wang H; Hardy E; Rosenstock J
Diabetes Obes Metab; 2018 Jul; 20(7):1602-1614. PubMed ID: 29473704
[TBL] [Abstract][Full Text] [Related]
38. A network meta-analysis to compare glycaemic control in patients with type 2 diabetes treated with exenatide once weekly or liraglutide once daily in comparison with insulin glargine, exenatide twice daily or placebo.
Scott DA; Boye KS; Timlin L; Clark JF; Best JH
Diabetes Obes Metab; 2013 Mar; 15(3):213-23. PubMed ID: 22958381
[TBL] [Abstract][Full Text] [Related]
39. Incretin-based therapies in clinical practice: from efficacy to effectiveness. Focus on liraglutide.
Ponzani P; Corsi A
Minerva Endocrinol; 2012 Mar; 37(1):1-8. PubMed ID: 22382611
[TBL] [Abstract][Full Text] [Related]
40. [Glucagon-like peptide 1 (GLP-1)].
Parhofer KG
MMW Fortschr Med; 2007 Jun; 149(25-26):41-3. PubMed ID: 17713050
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
